Small molecule • Aging & cellular biology
Dasatinib + quercetin
Also called D+Q senolytic combination
What it is, the potential benefits being studied, and what the evidence supports right now.
Early human research•Research-stage compound
01 • Start here
Potential benefits being studied.
Cellular senescence and age-related disease hypotheses.
- Cellular energy & aging
02 • Why it stands out
The simple explanation.
Dasatinib + quercetin is getting attention for cellular senescence and age-related disease hypotheses.
03 • Research highlight
Why researchers are interested.
Early work in people makes cellular senescence and age-related disease hypotheses the main reason to keep watching Dasatinib + quercetin.
Evidence detailsStudy limits, status, and safety context
Study summary: Small pilot studies have measured feasibility, biomarkers, or disease-specific outcomes; clinical benefit and long-term safety remain unestablished.
What to keep in mind: Dasatinib is a prescription cancer drug with serious risks. Early senolytic research is not a wellness protocol.
Potential benefits describe research questions, not a promise that a product will produce the same result in a person.